MDT Medtronic PLC

Highlighting the Evolution of High-Density Programming with Adaptive Stimulation

MINNEAPOLIS - December 11, 2014 - Medtronic, Inc. (NYSE: MDT) will exhibit a variety of innovations focused on providing patients with better pain relief and improving the overall patient experience during the North American Neuromodulation Society's annual meeting, December 11-14, 2014, in Las Vegas.

Specifically, Medtronic will highlight the following advancements that demonstrate Medtronic's leadership in the field of spinal cord stimulation (SCS) therapy for the treatment of chronic pain:

Advanced SCS Programming Options: Medtronic's AdaptiveStim® technology harnesses motion sensor technology to provide effective pain relief and convenience by automatically adapting SCS levels to the needs of people with chronic back and/or leg pain as they change position. Medtronic is now showcasing a variety of high-density (HD) programming options, called AdaptiveStim^®HD, which are available today. These advanced programming options give clinicians the unprecedented ability to deliver stimulation with or without paresthesia (a tingling sensation associated with traditional stimulation) and personalize spinal cord stimulation to meet the individual needs of patients. Medtronic will be launching new clinical investigations looking at high density stimulation using AdaptiveStimtechnology with studies focused on patient selection and parameter optimization, with the goal to advance innovations that enhance the patient experience.

SureScan^® MRI Spinal Cord Stimulation Systems: The first and only implantable SCS systems approved by the FDA for use in the treatment of chronic, intractable back and/or limb pain that provide patients with access to the benefits of MRI anywhere on the body under specific conditions*.

Previously, SCS patients were limited to only MRI head scans because of concerns of the system being affected by the large magnetic fields and radio frequency energy involved in MRI. Medtronic SureScan SCS systems address these concerns by including enhancements to existing devices, as well as specially designed leads, to reduce or eliminate the hazards produced by the MRI environment. The systems also include a proprietary SureScan programming feature, which sets the neurostimulator into an appropriate mode for the MRI environment. This enables radiology departments to easily and conveniently confirm that a patient's implantable system is safe for MRI scanning.

"Medtronic is looking forward to a great meeting celebrating the 20^th anniversary of the North American Neuromodulation Society," said Julie Foster, vice president and general manager of the Pain Stimulation and Targeted Drug Delivery (TDD) businesses at Medtronic Neuromodulation. "Chronic pain affects an estimated 116 million American adults, and it is terrific to see the interest in various forms of advanced programming capabilities, like AdaptiveStim HD, which gives physicians important options to tailor the therapy to the unique needs of patients living with chronic pain."

Medtronic neurostimulation therapy for chronic pain uses a medical device placed under a patient's skin to deliver mild electrical impulses to the spinal cord, which act to block pain signals from going to the brain. Since Medtronic developed the therapy in partnership with physicians in the 1980s, Medtronic neurostimulation therapy has helped nearly 200,000 people worldwide manage their chronic pain and enhance their lives.

With investments in more than 75 physician-sponsored studies and the largest product registry in the industry with over 10,000 patients, Medtronic continues to work closely with clinical thought leaders to generate a comprehensive portfolio of evidence demonstrating the clinical and economic value of its SCS and TDD systems for the management of chronic pain, and to address the knowledge gaps that exist in today's pain management therapies.

Medtronic's Leadership in Neuromodulation
Medtronic developed and leads the field of neuromodulation, the targeted and regulated delivery of electrical pulses and pharmaceuticals to specific sites in the nervous system. The company's Neuromodulation business includes implantable neurostimulation and targeted drug delivery systems for the management of chronic pain, common movement disorders, spasticity and urologic and gastrointestinal disorders.

About Medtronic
Medtronic, Inc. (www.medtronic.com), headquartered in Minneapolis, Minnesota, is the global leader in medical technology - alleviating pain, restoring health, and extending life for millions of people around the world.

Any forward-looking statements are subject to risks and uncertainties such as those described in Medtronic's periodic reports on file with the Securities and Exchange Commission. Actual results may differ materially from anticipated results.

*Under specific conditions. Refer to approved labeling.

- end -

Contacts:
Justin Ihle
Public Relations
+1-763-526-0911

Jeff Warren
Investor Relations
+1-763-505-2696

Medtronic (NYSE:MDT)
Historical Stock Chart
From Mar 2024 to Apr 2024

Medtronic (NYSE:MDT)
Historical Stock Chart
From Apr 2023 to Apr 2024